NCT01526096CompletedPhase 1
Stem Cell Transplantation for Patients With Multiple Myeloma
Pilot Study T Cell Depletion in the Setting of Autologous Stem Cell Transplantation for Patients With Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 5 Nov 2025
Brief summary (registry, in English)
The purpose of this study is to test whether regulatory T-cell reduction is possible and safe in myeloma subjects undergoing autologous stem cell transplantation (ASCT).
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 10 Aug 2011
- Start date
- 12 Jul 2011
- Primary completion date
- 28 Aug 2024
- Lead sponsor
- University of Chicago
- Diseases
- Multiple myeloma
- NCT number
- NCT01526096
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- From 12 Jul 2011 to the primary completion date, 28 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of systemic immunosuppressive medications, including corticosteroids, tacrolimus, mycophenolate mofetil, sirolimus or cyclosporine A.
Other illness
- Psychiatric illness which may make compliance to the clinical protocol unmanageable or which may compromise the ability of the patient to give informed consent.
- Active autoimmune disease including but not limited to: rheumatoid arthritis inflammatory bowel disease, celiac disease, systemic lupus erythematosis, scleroderma or multiple sclerosis.
Age
- Pregnant or nursing women. Women of child-bearing age must be tested for pregnancy.
Who the study is looking for
- Symptomatic multiple myeloma of any subtype in any disease stage, providing that patient does not have smoldering myeloma.
- Patient must otherwise be a candidate for ASCT as determined by treating physician.
- No current CNS Myeloma at time of enrollment.
- Life expectancy greater than 12 weeks.
- Age greater than or equal to 21 and less than or equal to 70 years old.
- EGOG performance status less than or equal to 2.
- No cardiac, pulmonary, hepatic, or renal contraindications for high dose chemotherapy.
- HIV Negative.
- No active Hepatitis B or C.
- Patients must be able to provide written informed, consent.
Age in the registry: 21 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.